Factors affecting cognitive function of opiate-dependent patients

Drug and Alcohol Dependence

Volumn 120, Issue 1-3, 2012, Pages 81-87

  Loeber, Sabine ^a   Nakovics, Helmut ^a   Kniest, Anja ^a   Kiefer, Falk ^a   Mann, Karl ^a   Croissant, Bernhard ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Cognitive impairment; Executive function; Opiate dependence; Treatment success

Indexed keywords

AMPHETAMINE DERIVATIVE; BUPRENORPHINE; COCAINE; METHADONE;

ADULT; AGE DISTRIBUTION; ALCOHOL CONSUMPTION; ARTICLE; ATTENTION; COCAINE DEPENDENCE; COGNITION; COGNITIVE DEFECT; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; DISEASE DURATION; EDUCATIONAL STATUS; EXECUTIVE FUNCTION; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; OPIATE ADDICTION; PATIENT MONITORING; PRIORITY JOURNAL; RESPONSE TIME; RISK FACTOR; SOCIOECONOMICS; SUBSTANCE ABUSE; TREATMENT DURATION;

ADULT; AGE FACTORS; COGNITION; COGNITION DISORDERS; DEPRESSION; EDUCATIONAL STATUS; EXECUTIVE FUNCTION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; OPIOID-RELATED DISORDERS; RISK FACTORS; SOCIOECONOMIC FACTORS; SUBSTANCE-RELATED DISORDERS; TIME FACTORS; YOUNG ADULT;

EID: 84155164760     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2011.07.001     Document Type: Article

References (38)

1. Applebaum A.J., Otto M.W., Richardson M.A., Safren S.A. Contributors to neuropsychological impairment in HIV-infected and HIV-uninfected opiate-dependent patients. J. Clin. Exp. Neuropsychol. 2010, 32:579-589.
2. Brickenkamp, R., 2002. d2 Aufmerksamkeits-Belastungstest. Hogrefe, Göttingen.
3. Cherner M., Letendre S., Heaton R.K., Durelle J., Marquie-Beck J., Gragg B., Grant I. Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine HIV Neurobehavioral Research Center Group. Neurology 2005, 64:1343-1347.
4. Czuchry M., Dansereau D.F. Cognitive skills training: impact on drug abuse counseling and readiness for treatment. Am. J. Drug Alcohol Abuse 2003, 29:1-18.
5. Czuchry M., Newbern-McFarland D., Dansereau D.F. Visual representation tools for improving addiction treatment outcomes. J. Psychoactive Drugs 2009, 41:181-187.
6. Danos P., Van Roos D., Kasper S., Brömel T., Broich K., Krappel C., Solymosi L., Möller H. Enlarged cerebrospinal fluid spaces in opiate-dependent male patients: a stereological CT study. Neuropsychobiology 1998, 38:80-83.
7. Darke S., Sims J., McDonald S., Wickes W. Cognitive impairment among methadone maintenance patients. Addiction 2000, 95:687-695.
8. Delis D.C., Kramer J., Kaplan E., Ober B.A. California Verbal Learning Test (CVLT) Manual 1987, Psychological Corporation, San Antonio, TX.
9. Ersche K.D., Clark L., London M., Robbins T.W., Sahakian B.J. Profile of executive and memory function associated with amphetamine and opiate dependence. Neuropsychopharmacology 2006, 31:1036-1047.
10. Ersche K.D., Sahakian B.J. The neuropsychology of amphetamine and opiate dependence: implications for treatment. Neuropsychol. Rev. 2007, 17:317-336.
11. Fernandez-Serrano M.J., Perez-Garcia M., Verdejo-Garcia A. What are the specific vs. generalized effects of drugs of abuse on neuropsychological performance?. Neurosci. Biobehav. Rev. 2011, 35:377-406.
12. Forton D.M., Thomas H.C., Murphy C.A., Allsop J.M., Foster G.R., Main J., Wesnes K.A., Taylor-Robinson S. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 2002, 35:433-439.
13. Gabilondo A.M., Meana J.J., Barturen F., Sastre M., García-Sevilla J.A. Mu-opioid receptor and alpha 2-adrenoceptor agonist binding sites in the postmortem brain of heroin addicts. Psychopharmacology 1994, 115:135-140.
14. Hanlon C.A., Wesley M.J., Stapleton J.R., Laurienti P.J., Porrino L.J. The association between frontal-striatal connectivity and sensorimotor control in cocaine users. Drug Alcohol Depend. 2011, 115:240-243.
15. Hautzinger M., Bailer M. Allgemeine Depressivitätsskala (ADS). Die deutsche Version des CES-D 1991, Beltz, Weinheim.
16. Hill S.Y., Reyes R.B., Mikhael M., Ayre F. A comparison of alcoholics and heroin abusers: computerized transaxial tomography and neuropsychological functioning. Curr. Alcohol 1979, 5:187-205.
17. Horton A.M., Roberts C. Derived Trail Making Test indices in a sample of heroin abusers: demographic effects. Int. J. Neurosci. 2002, 112:225-234.
18. Husain M., Mehta M.A. Cognitive enhancement by drugs in health and disease. Trends Cogn. Sci. 2011, 5:28-36.
19. Hyde J.S. The gender similarities hypothesis. Am. Psychol. 2005, 60:581-592.
20. Kirby K.N., Petry N.M., Bickel W.K. Heroin addicts have higher discount rates for delayed rewards than non-drug-using controls. J. Exp. Psychol. Gen. 1999, 128:78-87.
21. Kumar A.M., Ownby R.L., Waldrop-Valverde D., Fernandez B., Kumar M. Human immunodeficiency virus infection in the CNS and decreased dopamine availability: relationship with neuropsychological performance. J. Neurovirol. 2011, 17:26-40.
22. Lundqvist T. Cognitive consequences of cannabis use: comparison with abuse of stimulants and heroin with regard to attention, memory and executive functions. Pharmacol. Biochem. Behav. 2005, 81:319-330.
23. Lynch G., Palmer L.C., Gall C.M. The likelihood of cognitive enhancement. Pharmacol. Biochem. Behav. 2011, 99:116-129.
24. Mattick R.P., Breen C., Kimber J., Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst. Rev. 2003, 8:CD002209.
25. Müller M.C., Pichler M., Martin G., Plörer D., Winter C., Pogarell O., Bogner J.R. Burden of disease and level of patient's medical care in substitution treatment for opiates. Med. Klin. (Munich) 2009, 104:913-917.
26. Ornstein T.J., Iddon J.L., Baldacchino A.M., Sahakian B.J., London M., Everitt B., Robbins J.T.W. Profiles of cognitive dysfunction in chronic amphetamine and heroin abusers. Neuropsychopharmacology 2000, 23:113-126.
27. Pezawas L.M., Fischer G., Diamant K., Schneider C., Schindler S.D., Thurnher M., Ploechl W., Eder H., Kasper S. Cerebral CT findings in male opioid-dependent patients: stereological, planimetric and linear measurements. Psychiatry Res. 1998, 83:139-147.
28. Prosser J., Cohen L.J., Steinfeld M., Eisenberg D., London E.D., Galynker I.I. Neuropsychological functioning in opiate-dependent subjects receiving and following methadone maintenance treatment. Drug Alcohol Depend. 2006, 84:240-247.
29. Prosser J., London E.D., Galynker I.I. Sustained attention in patients receiving and abstinent following methadone maintenance treatment for opiate dependence: performance and neuroimaging results. Drug Alcohol Depend. 2009, 104:228-240.
30. Reitan R.M. Trail Making Test. Manual for Administration and Scoring 1992, Reitan Neuropsychology Laboratory, Tucson, AZ.
31. Rounsaville B., Jones J., Novelly C.R., Kleber A.H. Neuropsychological functioning in opiate addicts. J. Nerv. Ment. Dis. 1982, 170:209-216.
32. Schmidt K.-H., Metzler P. Wortschatztest (WST) 1992, Beltz Test GmbH, Weinheim.
33. Schuhfried G. Wiener Testsystem. Psychologische Diagnostik 2005, Schuhfried, Mödling.
34. Tate R.L., Fenelon B., Manning M.L., Hunter M. Patterns of neuropsychological impairment after severe blunt head injury. J. Nerv. Ment. Dis. 1991, 179:117-126.
35. Valcour V., Paul R., Neuhaus J., Shikuma C. The effects of age and HIV on neuropsychological performance. J. Int. Neuropsychol. Soc. 2011, 17:190-195.
36. Verdejo A., Toribio I., Orozco C., Puente K., Pérez-García L.M. Neuropsychological functioning in methadone maintenance patients versus abstinent heroin abusers. Drug Alcohol Depend. 2005, 78:283-288.
37. Wang G.J., Volkow N.D., Fowler J.S., Logan J., Abumrad N.N., Hitzemann R.J., Pappas N.S., Pascani K. Dopamine D2 receptor availability in opiate-dependent subjects before and after naloxone-precipitated withdrawal. Neuropsychopharmacology 1997, 16:174-182.
38. Woicik P.A., Moeller S.J., Alia-Klein N., Maloney T., Lukasik T.M., Yeliosof O., Wang G.J., Volkow N.D., Goldstein R.Z. The neuropsychology of cocaine addiction: recent cocaine use masks impairment. Neuropsychopharmacology 2009, 34:1112-1122.